Pain Management

>

Latest News

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect
Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

January 13th 2025

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

FDA Assigns PDUFA Date for TNX-102 SL, a Nonopioid Analgesic for Fibromyalgia
FDA Assigns PDUFA Date for TNX-102 SL, a Nonopioid Analgesic for Fibromyalgia

January 2nd 2025

Vertex Nonopioid Analgesic on Par with Placebo in Phase 2 Study of Lumbosacral Radiculopathy  / image credit ©decade3D/stock.adobe.com
Vertex Nonopioid Analgesic on Par with Placebo in Phase 2 Study of Lumbosacral Radiculopathy

December 19th 2024

FDA accepts NDA for TNX-102 SL, Tonix Pharmaceuticals nonopioid analgesic for fibromyalgia  / image credit FDA HQ ©Tada Images/stock.adobe.com
FDA Accepts NDA for TNX-102 SL, Tonix Nonopioid Analgesic for Fibromyalgia

December 17th 2024

Suzetrigine Phase 3 Data Presented During "Best Abstract" Session at Anesthesiologists' Annual Meeting / image credit postop concept: ©Justlight AI/stock.adobe.com
Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting

October 21st 2024

Latest CME Events & Activities

Individualizing Treatment for Patients with Generalized Myasthenia Gravis

View More

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

March 1, 2025

Register Now!

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders

View More

BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions

View More

Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Carolina Neuromuscular Disease Summit

September 27, 2025

Register Now!

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

View More

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

View More

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

View More

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

View More

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

View More

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

View More

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

View More

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

View More

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

View More

More News

© 2025 MJH Life Sciences

All rights reserved.